Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 4 bp deletion in exon 13.,
Disease:Adenocarcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-FANCD2, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Zygosity-Homozygous, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
FANCD2 also known as Fanconi anemia group D2 functions mechanically in DNA repair processes. This protein plays a role in the cellular response to DNA damage specifically interstrand crosslinks. FANCD2 has a molecular weight of approximately 164 kDa. Expression of FANCD2 occurs broadly in various tissues but reaches higher levels in cells that undergo rapid division such as hematopoietic cells.
Biological function summary
FANCD2 collaborates with multiple proteins as part of the Fanconi anemia (FA) complex to ensure genomic stability. The FA complex operates by facilitating the repair of DNA interstrand crosslinks that impede replication. FANCD2 becomes activated through monoubiquitination which serves as a signal for recruitment to DNA damage sites. It essentially functions as a coordinator that brings together important components for repair.
Pathways
FANCD2 integrates into the Fanconi anemia pathway and the homologous recombination repair pathway. These pathways are critical for maintaining DNA integrity and preventing chromosomal instability. Within these pathways interactions with proteins such as BRCA1 and BRCA2 reinforce the repair processes. FANCD2's connection to these proteins exemplifies its role in complex mechanisms that preserve genomic fidelity.
FANCD2 links significantly to Fanconi anemia a genetic disorder that causes bone marrow failure and increased cancer susceptibility. Damage or malfunction of FANCD2 can disrupt DNA repair leading to cellular dysfunction seen in this condition. Additionally there is a connection to breast cancer whereby FANCD2 interacts with BRCA2 indicating a shared pathway involved in tumor suppressor functions. These associations underline the importance of FANCD2 in disease pathology and its potential as a therapeutic target.
